Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Background High‐dose chemotherapy plus autologous stem‐cell transplantation has been the standard treatment for newly diagnosed… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2016
Highly Cited
2016
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • table 4
Highly Cited
2010
Highly Cited
2010
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2008
Highly Cited
2008
BACKGROUND The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Review
2006
Review
2006
PURPOSE Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2005
Highly Cited
2005
BACKGROUND This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Review
2004
Review
2004
The dipeptide boronic acid analogue VELCADE™ (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective… Expand
Highly Cited
2004
Highly Cited
2004
In a phase 2 open‐label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed… Expand
Review
2003
Review
2003
BACKGROUND Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1… Expand
  • table 1
  • table 2
  • figure 1
  • table 3